Direct measurement of spatial modes of a micro-cantilever from thermal noise

International audienceMeasurements of the deflection induced by thermal noise have been performed on a rectangular atomic force microscope cantilever in air. The detection method, based on polarization interferometry, can achieve a resolution of 1E-14 m/rtHz in the frequency range 1 kHz – 800 kHz. The focused beam from the interferometer probes the cantilever at different positions along its length and the spatial modes' shapes are determined up to the fourth resonance, without external excitation. Results are in good agreement with theoretically expected behavior. From this analysis accurate determination of the elastic constant of the cantilever is also achieved

Effectiveness of endoscopic trans-tendineous repair for partial-thickness tears of medius gluteus: A systematic review of literature

Tears of the gluteus medius can result in chronic hip pain over time. Pathological onsets involving the gluteus medius cause pain and weakness of abductor strength. Endoscopic repair is a suitable, effective and safe surgical alternative to traditional open techniques and give satisfactory results over time restoring the footprint of gluteus medius. The purpose of this systematic review is to analyse the effectiveness of endoscopic trans-tendinous technique for partial-thickness tears, analysing the subjective and functional outcome over the time. A search of literature (PubMed, Scopus, WebOfKnowledge) was performed. The PRISMA method was used to screen the articles. A total of 4 articles was screened and included for qualitative analysis. For data extraction patient characteristics, pre-clinical examination, imaging, timing from symptoms to surgery, technique performed, subjective scales, functional outcomes, post-operative clinical assessment were analysed. Subjective scores at mean follow-up of 18 months show a significative improvement in all the scales reported, in relief of pain (VAS score) and in terms of strength of abductor. Trans-tendinous technique represents the gold standard to treat endoscopically these injuries. Furthermore, other studies with larger number of patients and longer follow-up are required to validate the best surgical approach for these injuries

ten year estimated risk of bone fracture in women with differentiated thyroid cancer under tsh suppressive levothyroxine therapy

Introduction: After thyroidectomy and radioiodine therapy, patients with differentiated thyroid cancer (DTC) are indefinitely treated with levothyroxine (L-T4). Osteoporosis is a debated consequence of hypothyroxinaemia. The aim of this study was to evaluate bone mineral density (BMD) and fracture risk assessed by FRAX in a cohort of DTC women. Material and methods: Seventy-four women with DTC (aged 56.5 ± 9.9 years) treated at the mean age of 51.9 ± 12.0 years were studied. Baseline BMD and FRAX were evaluated after 3.0 years (median). BMD and FRAX were further evaluated 5.5 years (median) after the baseline evaluation. A cohort of 120 euthyroid women, matched for age, BMI, and menopausal status, were evaluated as controls. Results: L-T4 dosages were 813.6 ± 208.8 μg/week and 782.1 ± 184.4 μg/week at the baseline and second evaluation, respectively. The risks of major osteoporotic fracture (MOF) and hip fracture (HF) were similar in DTC patients and in controls. In DTC women, significant changes in FRAX were found, with a higher increase in the probability of HF than of MOF. A similar change was found in controls. A significant inverse correlation (P < 0.001) between L-T4 dosage and HF/MOF probability on both first and second evaluations was found. A significant inverse correlation (P = 0.05) was found between fT4, TSH and duration of therapy and HF/MOF probability only on the second evaluation. Conclusions: FRAX increase is a multi-factorial, age-related phenomenon. The absence of correlations between L-T4 dosage, length of therapy or fT4 levels and FRAX does not enable us to attribute an increased fracture risk to DTC women with well-controlled disease on therapy. (Endokrynol Pol 2016; 67 (4): 350–358

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study

Background: Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. Methods: This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Findings: Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p < 0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05–2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p < 0·001). Interpretation: Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure &lt; 100 mmHg (n = 1127), estimated glomerular filtration rate &lt; 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Transcardiac thyroid hormone variation induced by myocardial hypoxia in patients undergoing cardiopulmonary bypass.

As doenças cardíacas são a principal causa de morte em todo o mundo. Os hormônios tireoidianos desempenham um papel chave no metabolismo miocárdico e na fisiologia do sistema cardiovascular. A doença cardíaca aguda ou crônica promove uma queda sistêmica da concentração dos hormônios tireoidianos que se associa a um prognóstico pior da doença e aumento da sua mortalidade. Essa redução dos hormônios tireoidianos pode ocorrer na presença de função normal da tireóide, entidade clínica conhecida por síndrome da doença não-tireoidiana ou síndrome do enfermo eutireoideo (SEE). A participação do músculo cardíaco na patogênese da SEE é desconhecida. O entendimento do papel do músculo cardíaco na SEE é essencial para o tratamento das doenças cardíacas. Este estudo se propõe a avaliar a variação dos hormônios tireoidianos promovida pelo metabolismo cardíaco nos pacientes submetidos a cirurgias cardíacas com diferentes graus de isquemia miocárdica aguda, bem como estudar os principais mecanismos envolvidos nessa variação. Para avaliar a variação sistêmica de hormônios tireoideanos induzida pela cirurgia cardíaca com e sem circulação extracorpórea (CEC), 35 pacientes com estenose aórtica grave e doença coronariana submetidos à cirurgia com CEC e 12 pacientes submetidos à cirurgia de revascularização miocárdica sem CEC tiveram as concentrações sistêmicas dos hormônios tireoidianos dosadas no início do procedimento cirúrgico, imediatamente antes do clampeamento da aorta, 3 minutos após o desclampeamento da aorta, 6 e 24h após o procedimento. Além disso, a avaliação da participação isolada do coração foi feita pela dosagem dos hormônios tireoidianos na raiz da aorta e no seio coronário antes e após a isquemia miocárdica aguda induzida pelo clampeamento da aorta. Foram ainda quantificadas, em amostras do tecido miocárdico colhidas após a CEC, a expressão do gene das desiodades, enzimas responsáveis pela conversão dos hormônios tireoidianos nos tecidos periféricos. Essas medidas sanguíneas foram comparadas, bem como a expressão das desiodases presentes no músculo cardíaco, relacionando a sua expressão à variação transcardíaca dos hormônios tireoidianos. O estudo demonstrou uma queda significativa de 37,6% da concentração periférica de T3 associada a uma elevação de 261,6% do rT3 e manutenção das concentrações séricas de T4 livre ao longo do acompanhamento perioperatório nos três grupos. Os resultados não mostraram diferença da variação periférica dos hormônios tireoidianos entre os grupos. Nas amostras centrais, observou-se uma redução transcardíaca de 4,6% de T3 com incremento de 6,9% do rT3, sem alterações do T4 total no grupo estenose aórtica antes do início da CEC. Esse comportamento, no entanto, não foi visto nos pacientes com doença arterial coronariana antes da CEC. Após cerca de 3 minutos de reperfusão miocárdica depois do término da CEC, as variações de concentração de T3 e de rT3 entre a aorta e o seio coronário se perderam. A análise do mRNA do tecido miocárdico indicou expressão significativa da desiodase tipo III com ausência de expressão da desiodase tipo II nos três grupos, sem diferença significativa entre elas. Dessa forma, pode-se concluir que as cirurgias cardíacas com CEC ou sem CEC estão associadas ao desenvolvimento da SEE e que a intensidade desse distúrbio metabólico é similar nos três tipos de procedimento, independente da CEC. Em relação à contribuição do coração para este fenômeno, a expressão das enzimas relacionadas à síndrome no tecido cardíaco foi observada em todos os grupos estudados, mas somente o grupo estenose aórtica demonstrou variação hormonal transcardíaca pré-CEC, com a isquemia miocárdica possivelmente neutralizando esse efeito após a CEC. É possível que a isquemia crônica provavelmente devido à hipertrofia miocárdica, e não a isquemia aguda causada pela CEC, tenha uma capacidade de modificar as concentrações dos hormônios tireoidianosHeart diseases are the main cause of death over the world and thyroid hormones are key elements in myocardial metabolism and cardiovascular physiology. In heart disease patients, low thyroid hormone levels lead to a worse prognosis and increase in the mortality, even with regular thyroid function, in a condition known as Euthyroid Sick Syndrome (ESS). There is no evidence that myocardial tissue is involved in ESS pathophysiology. The better understanding of heart role might be important to optimal treatment of heart disease. The current study aims to evaluate thyroid hormones variation induced by myocardial metabolism in patients submitted to several acute myocardial ischemic intensities and study the main mechanisms associated to this condition. To reach this objective, 35 stable severe aortic stenosis coronary artery disease submitted to in-pump cardiac surgery and 12 patients submitted to off-pump myocardial revascularization surgery were analyzed at the procedure beginning, before aortic clamping, 3 minutes after aortic cross-clamp release, six and 24h after procedure by measuring thyroid hormones concentration in systemic circulation. Therefore, cardiac metabolism was evaluated alone by the thyroid hormones concentration measurement in aortic root and coronary sinus just before and after myocardial ischemia induced by aortic clamping, as well the gene expression of thyroid hormones metabolism related enzyme in myocardial tissue samples. There was a significant 37.6% reduction in T3 systemic concentration, a 261.6% elevation in rT3 and no variation in free T4 systemic values during the observation time in three groups. However, there were no statistically differences among the groups. Central analysis showed a 4.6% significant reduction in T3 and 6.9% increase in rT3 in coronary sinus, compared to aortic root, in aortic stenosis group before cardiopulmonary bypass. The same behavior was not observed in coronary artery disease before aortic cross clamping. After cardiopulmonary bypass, no differences were seen in any group. However, Deiodinase Type III, which is responsible for the T3 concentration decrease, gene RNA-m expression was detected in all myocardial tissue biopsies, and the Deiodinase Type II, which produces T3 from T4, was absent in myocardial tissue during the heart surgery. In conclusion, in- or off-pump heart surgeries are associated to similar systemic ESS intensities and to ESS-enzyme related gene expressions in myocardial tissue. However, myocardial metabolism in aortic stenosis patients is able to change thyroid hormones concentrations, probably due to myocardial hypertrophy and chronic ischemia assault, which were no observed in coronary disease patient